Revenue jumped 78% on Brazil, but FY24 US seedling guidance cut

Revenue rose 78.4% to US$13.2m, an outcome management attributes to record sales volumes in Brazil. The supplied historical baseline classifies this growth as above the company's normal half-year range; the three-period mean is 2.4% against a range of -61.3% to 60.9%.

Profitability moved less dramatically. PBT improved 6.3% to a US$1.5m loss, while NPAT narrowed to a US$0.1m loss (+93.8%) on a 93.3% effective tax rate versus 0.0% in the prior comparable. Operating cash flow swung from -US$2.4m to +US$2.1m, but the cash balance still fell 48.8% to US$4.3m and inventories grew 11.2% to US$46.7m.

HY23 represented only 13.2% of FY23 revenue, so the second half does the heavy lifting in this business. Management has now flagged US seedling sales below original expectations for that very period, which means a naive doubling of H1 understates the importance of the downgrade.

PBT growth is the cleaner read on operations. The reported +93.8% NPAT improvement reflects an effective tax rate of 93.3% versus 0.0% in HY23, not a sevenfold acceleration in operating progress. Annolyse's historical baseline classifies PBT growth of 6.3% as above the prior three-period mean of -78.7%, but a near-flat loss line is a more honest description of underlying operating performance than the NPAT headline.

Revenue concentration in Brazil raises mix durability questions. Management explicitly credits Brazil for the half's strength while flagging weakness in the US franchise. With Brazil providing the upside and the US providing the downgrade, geographic mix rather than aggregate growth becomes the key analytical question.

The shape context is unambiguous: FY23 generated US$48.7m in H2 against US$7.4m in H1, an extreme second-half skew tied to the seedling planting cycle. A guidance cut targeted at US seedlings in that second half therefore matters more than the percentage uplift in the first half suggests.

What the release supports is that Brazil is over-delivering and the US business is under-delivering versus prior expectations. What it does not support is any quantification of the net effect on FY24 revenue or earnings.

Inventories grew US$4.7m to US$46.7m, which inflates working capital and represents future cash that has not yet been released. Capex rose 20.8% to US$2.9m, leaving pre-lease free cash flow at -US$0.8m. The historical baseline classifies that as above the normal range (three-period mean -US$4.6m), so the FCF burn has narrowed meaningfully — but the cash balance still fell US$4.1m over the period, partly through debt repayment, indicating the balance sheet is still funding the cycle.

Tax accounting is also doing work. A 93.3% effective rate against the historical mean of 38.1% drove most of the gap between PBT and NPAT growth (-87.5pp). Investors reading the +93.8% NPAT line should view the +6.3% PBT line as the underlying signal.

This briefing cannot assess the magnitude of the FY24 guidance revision or the nature of the amendment because neither was quantified in the supplied release excerpts.